A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news ...

Eli Lilly is leading the market for GLP-1 medications (for weight loss and diabetes). In a decade, Eli Lilly could be in the ...

LLY's explosive GLP-1 growth, deep obesity pipeline and strong estimate momentum give it the edge over MRK despite a richer ...

US health technology assessor the Institute for Clinical and Economic Review (ICER) today released a Final Evidence Report ...

In November, the Trump administration resurrected a Most Favored Nation (MFN) reference pricing policy, which would tie drug ...

There is no exact known number of GLP-1 patients who say their say their sense of taste has changed since starting the ...

Today, Form Health, the national leader in science-based obesity and cardiometabolic care, announced access to new programs that provide employers with transparent, predictable access to obesity ...

Grand View Research found that North America accounts for the largest revenue share, with more than 75% of the GLP-1 agonists market. While other alternative obesity interventions exist, including ...

If the enhanced credits currently available to Affordable Care Act (ACA) Marketplace enrollees are allowed to expire for 2026 ...

With a market capitalization approaching the $1 trillion mark, Eli Lilly is engaged in a close competitive race with Novo Nordisk for dominance in the obesity treatment sector. Market researchers ...

A federal judicial panel on Monday ordered that a growing number of lawsuits accusing Novo Nordisk and Eli Lilly of causing ...